IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3357-3365

  Rao, Jay B ^a,b   Chamberlain, Ronald S ^b   Bronte, Vincenzo ^b   Carroll, Miles W ^c   Irvine, Kari R ^b   Moss, Bernard ^c   Rosenberg, Steven A ^b   Restifo, Nicholas P ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA GALACTOSIDASE; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; TUMOR ANTIGEN; TUMOR VACCINE; VACCINIA VACCINE;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; SPLEEN; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0029885750     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Moss, B. 1991. Vaccinia virus: a tool for research and vaccine development. Science 252:1662.
2. Moss, B. 1993. Poxvirus vectors: cytoplasmic expression of transferred genes. Curr. Opin. Genet. Dev. 3:86.
3. Restifo, N. P., I. Bacik, K. R. Irvine, J. W. Yewdell, B. J. McCabe, R. W. Anderson, L. C. Eisenlohr, S. A. Rosenberg, and J. R. Bennink. 1995. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:4414.
4. Wang, M., V. Bronte, P. W. Chen, L. Gritz, D. Panicali, S. A. Rosenberg, and N. P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowl poxvirus encoding a model tumor-associated antigen. J. Immunol. 154:4685.
5. Bronte, V., K. Tsung, J. B. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N. P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154: 5282.
6. Mackett, M., G. L. Smith, and B. Moss. 1992. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Biotechnology 24:495.
7. Blancou, J., M. P. Kieny, R. Lathe, J. P. Lecocq, P. P. Pastoret, J. P. Soulebot, and P. Desmettre. 1986. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 322:373.
8. Kantor, J., K. Irvine, S. Abrams, H. Kaufman, J. DiPietro, and J. Schlom. 1992. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84:1084.
9. Estin, C. D., U. S. Stevenson, G. D. Plowman, S. L. Hu, P. Sridhar, I. Hellstrom, J. P. Brown, and K. E. Hellstrom. 1988. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc. Natl. Acad. Sci. USA 85:1052.
10. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
11. Scharton-Kersten, T., L. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320.
12. Ghalib, H. W., J. A. Whittle, M. Kubin, F. A. Hashim, A. M. el-Hassan, K. H. Grabstein, G. Trinchieri, and S. G. Reed. 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154:4623.
13. Murray, H. W., and J. Hariprashad. 1995. Interleukin-12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J. Exp. Med. 181:387.
14. Hunter, C. A., E. Candolfi, C. Subauste, V. Van Cleave, and J. S. Remington. 1995. Studies on the role of interleukin-12 in acute murine toxoplasmosis. Immunology 84:16.
15. Wynn, T. A., D. Jankovic, S. Hieny, A. W. Cheever, and A. Sher. 1995. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia. J. Immunol. 154:4701.
16. Sieling, P. A., X. H. Wang, M. K. Gately, J. L. Oliveros, T. McHugh, P. F. Barnes, S. F. Wolf, L. Golkar, M. Yamamura, and Y. Yogi. 1994. IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J. Immunol. 153:3639.
17. Gazzinelli, R. T., N. A. Giese, and H. C. Morse. 1994. In vivo treatment with interleukin 12-protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J. Exp. Med. 180:2199.
18. Wynn, T. A., I. Eltoum, I. P. Oswald, A. W. Cheever, and A. Sher. 1994. Endogenous interleukin-12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J. Exp. Med. 179:1551.
19. Tahara, H., H. J. Zeh, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182.
20. Noguchi, Y., E. C. Richards, Y. T. Chen, and L. J. Old. 1995. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
21. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178:1223.
22. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, and W. J. Storkus. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
23. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25:137
24. Boussiotis, V. A., J. G. Gribben, G. J. Freeman, and L. M. Nadler. 1994. Blockade of the CD28 costimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6:797.
25. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
26. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
27. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J. Exp. Med. 173:721.
28. Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261.
29. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp. Med. 181: 619.
30. + T cells by B7-transfected melanoma cells. Science 259:368.
31. Kubin, M., M. Kamoun, and G. Trinchieri. 1994. Interleukin-12 synergizes with B7-CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180:211.
32. Murphy, E. E., G. Terres, S. E. Macatonia, C. S. Hsieh, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, and A. O'Garra. 1994. B7 and interleukin-12 cooperate for proliferation and interferon-γ production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180:223.
33. - mutation. Proc. Natl. Acad. Sci. USA 85:2274.
34. Boon, T., J. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
35. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
36. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
37. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
38. Robbins, P. F., M. El-Gamil, Y. Kawakami, E. Stevens, J. R. Yannelli, and S. A. Rosenberg. 1994. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124.
39. Smith, G. L., J. Z. Levin, P. Palese, and B. Moss. 1987. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology 160:336.
40. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157.
41. Kaplan, E. L. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457.
42. Karupiah, G., R. V. Blanden, and I. A. Ramshaw. 1990. Interferon-γ is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin-2 infection. J. Exp. Med. 172:1495.
43. Gajewski, T., J. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cutotoxic T lymphocytes in vitro. J. Immunol. 154:5638.
44. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller, B. S. McEwen, and C. A. Biron. 1995. Mechanism of interleukin-12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181:901.
45. Coutelier, J. P., J. Van Broeck, and S. F. Wolf. 1995. Interleukin-12 gene expression after viral infection in the mouse. J. Virol. 69:1955.
46. Tang, Y., and B. Graham. 1995. Interleukin-12 increases the immunogenicity of RSV vaccination. IL-12 in Infection (Abstr.).
47. Jenkins, M. K., and J. G. Johnson. 1993. Molecules involved in T cell costimulation. Curr. Opin. Immunol. 5:361.
48. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor. 1994. Induction of anti-tumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54:5552.
49. Walter, H., S. Schepensn, J. Van Wauwe, and M. De Boer. 1994. Ligation of CD28 on resting T cells by its ligand B7 results in the induction of both Th1- and Th2-type cytokines. Eur. Cytokine Netw. 5:13.
50. L. Immunity 3:87.
51. Kundig, T. M., M. F. Bachmann, L. Lefrancois, L. Puddington, H. Hengartner, and R. M. Zinkernagel. 1993. Nonimmunogenic tumor cells may efficiently re-stimulate tumor antigen-specific cytotoxic T cells. J. Immunol. 150:4450.
52. Ressing, M. E., A. Sette, R. M. Brandt, J. Ruppert, P. A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 154:5934.
53. Chen, W., D. J. Peace, D. K. Rovira, S. G. You, and M. A. Cheever. 1992. T cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA 89:1468.
54. Boon, T., J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
55. Townsend, A., C. Ohlen, M. Rogers, J. Edwards, S. Mukherjee, and J. Bastin. 1994. Source of unique tumour antigens. Nature 371:662.